ArticleHealth and quality of life outcomes2018
The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation.
Article in Health and quality of life outcomes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Quality of Life in Japanese Men Treated with Intensity Modulated Radiotherapy for Localized Prostate Cancer: Three-Year Longitudinal Evaluation Using Patient-Reported Outcomes of the Expanded Prostate Index Composite (EPIC).Journal of clinical medicine · 2026Article
- Article
- Article
- Patient-reported Outcome Measures and Decision Regret After Prostate-specific Membrane Antigen-targeted Radioguided Surgery for Oligorecurrent Prostate Cancer.European urology open science · 2024Article
- The Romanian translation and validation of the Extended Prostate Cancer Index Composite in patients undergoing radical prostatectomy.Medicine and pharmacy reports · 2024Article
- Article
- Missingness in the expanded prostate cancer index short form (EPIC-26) - prevalence, patterns, and explanatory factors.Health and quality of life outcomes · 2023Article
- Article
- Hemorrhagic Cystitis: Making Rapid and Shrewd Clinical and Surgical Decisions for Improving Patient Outcomes.Research and reports in urology · 2023Review
- Symptom burden and health-related quality of life six months after hyperbaric oxygen therapy in cancer survivors with pelvic radiation injuries.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Creation and validation of the harmonized Arabic version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP).Arab journal of urology · 2022Article
- Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD®) for Localized Prostate Cancer.Urologia internationalis · 2022Article
- Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain.Health and quality of life outcomes · 2021Observational
- Dose-volume histogram parameters and patient-reported EPIC-Bowel domain in prostate cancer proton therapy.Radiation oncology journal · 2021Article
- Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer.World journal of urology · 2021Article
- Measuring Quality of Life Following Robot-Assisted Radical Prostatectomy.Patient preference and adherence · 2021Review
- Validation of the Italian version of the abbreviated expanded prostate Cancer index composite (EPIC-26) in men with prostate Cancer.Health and quality of life outcomes · 2019Article
- Development and Validation of Crosswalks for Patient-reported Sexual and Urinary Outcomes Between Commonly Used Instruments.European urology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNo official German translation exists for the 50-item Expanded Prostate Cancer Index Composite (EPIC), and no minimal important difference (MID) has been established yet. The aim of the study was to translate and validate a German version of the EPIC with cultural adaptation to the different German speaking countries and to establish the MID.
methodsWe translated and culturally adapted the EPIC into German. For validation, we included a consecutive subsample of 92 patients with localized prostate cancer undergoing radical prostatectomy who participated the Prostate Cancer Outcomes Cohort. Baseline and follow-up assessments took place before and six weeks after prostatectomy in 2010 and 2011. We assessed the EPIC, EORTC QLQ-PR25, Feeling Thermometer, SF-36 and a global rating of health state change variable. We calculated the internal consistency, test-retest reliability, construct validity, responsiveness and MID.
resultsFor most EPIC domains and subscales, our a priori defined criteria for reliability were fulfilled (construct reliability: Cronbach's alpha 0.7-0.9; test-retest reliability: intraclass-correlation coefficient ≥ 0.7). Cross-sectional and longitudinal correlations between EPIC and EORTC QLQ-PR25 domains ranged from 0.14-0.79, and 0.06-0.5 and 0.08-0.72 for Feeling Thermometer and SF-36, respectively. We established MID values of 10, 4, 12, and 6 for the urinary, bowel, sexual and hormonal domain.
conclusionThe German version of the EPIC is reliable, responsive and valid to measure HRQL in prostate cancer patients and is now available in German language. With the suggested MID we provide interpretation to what extent changes in HRQL are clinically relevant for patients. Hence, study results are of interest beyond German speaking countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.